文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

评估卡拉胶鼻喉喷雾预防COVID-19有效性的双盲随机安慰剂对照试验研究方案——ICE-COVID

A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
PubMed 文献 · Trials · 2022-09-15

本研究为单中心、随机、双盲、安慰剂对照III期试验,旨在评估卡拉胶鼻喉喷雾用于COVID-19预防的有效性。参与者按1:1随机分配至治疗组(Coldamaris plus喷雾,含1.2 mg iota-卡拉胶、0.4 mg kappa-卡拉胶、0.5%氯化钠)或安慰剂组(Coldamaris sine喷雾,含0.5%氯化钠),每日鼻喉喷雾持续8周,并完成每日症状追踪问卷共10周。主要结局为研究期间症状出现时PCR拭子阳性或血清学转换确诊的COVID-19感染。

要点

  • 卡拉胶鼻喉喷雾在临床试验中显示对多种病毒有效,通过阻止病毒进入呼吸道宿主细胞发挥作用。
  • 卡拉胶在体外实验中显示对SARS-CoV-2具有活性。
  • 本研究为单中心、随机、双盲、安慰剂对照III期试验,每日鼻喉喷雾持续8周,随访问卷共10周。

核心结论

  • 本研究旨在评估卡拉胶鼻喉喷雾是否能降低COVID-19的发生风险和严重程度。
  • 若被证明有效,这种自我给药的预防性喷雾将对关键工作人员和普通人群有更广泛的用途。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照III期试验。
  • 参与者按1:1分配至治疗组(Coldamaris plus喷雾,含1.2 mg iota-卡拉胶(Carragelose®)、0.4 mg kappa-卡拉胶、0.5%氯化钠和纯化水)或安慰剂组(Coldamaris sine喷雾,含0.5%氯化钠)。
  • 每日鼻喉喷雾持续8周,并完成每日症状追踪问卷共10周。

主要发现

  • 主要结局:研究期间症状出现时PCR拭子阳性或血清学转换确诊的COVID-19感染。
  • 次要结局包括症状类型、严重程度和持续时间,后续家庭/家庭成员COVID-19感染以及非COVID-19上呼吸道感染。
  • 将进行试验内经济评估,效果以质量调整生命年表示。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: At present, vaccines form the only mode of prophylaxis against COVID-19. The time needed to achieve mass global vaccination and the emergence of new variants warrants continued research into other COVID-19 prevention strategies. The severity of COVID-19 infection is thought to be associated with the initial viral load, and for infection to occur, viruses including SARS-CoV-2 must first penetrate the respiratory mucus and attach to the host cell surface receptors. Carrageenan, a sulphated polysaccharide extracted from red edible seaweed, has shown efficacy against a wide range of viruses in clinical trials through the prevention of viral entry into respiratory host cells. Carrageenan has also demonstrated in vitro activity against SARS-CoV-2. METHODS AND ANALYSIS: A single-centre, randomised, double-blinded, placebo-controlled phase III trial was designed. Participants randomised in a 1:1 allocation to either the treatment arm, verum Coldamaris plus (1.2 mg iota-carrageenan (Carragelose®), 0.4 mg kappa-carrageenan, 0.5% sodium chloride and purified water), or placebo arm, Coldamaris sine (0.5% sodium chloride) spray applied daily to their nose and throat for 8 weeks, while completing a daily symptom tracker questionnaire for a total of 10 weeks. PRIMARY OUTCOME: Acquisition of COVID-19 infection as confirmed by a positive PCR swab taken at symptom onset or seroconversion during the study. Secondary outcomes include symptom type, severity and duration, subsequent familial/household COVID-19 infection and infection with non-COVID-19 upper respiratory tract infections. A within-trial economic evaluation will be undertaken, with effects expressed as quality-adjusted life years. DISCUSSION: This is a single-centre, phase III, double-blind, randomised placebo-controlled clinical trial to assess whether carrageenan nasal and throat spray reduces the risk of development and severity of COVID-19. If proven effective, the self-administered prophylactic spray would have wider utility for key workers and the general population. TRIAL REGISTRATION: NCT04590365; ClinicalTrials.gov NCT04590365. Registered on 19 October 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jessop ZM, Gibson J, Lim JY, et al. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID. Trials. 2022. PMID: 36109791. doi:10.1186/s13063-022-06685-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。